Uncontrolled blood pressure in a treated, high-risk managed care population

American Journal of Managed Care

Volumn 11, Issue SUPPL. 7, 2005, Pages

  Andros, Vickie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG INDICATION; DRUG UTILIZATION; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYSTEMATIC REVIEW; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; DATA COLLECTION; HUMANS; HYPERTENSION; MANAGED CARE PROGRAMS; TREATMENT OUTCOME; UNITED STATES;

EID: 25444512398     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas, Tex: American Heart Association; 2005.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-1576.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
5. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287:1003-1010.
6. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7. Hypertension. 2003;42:1206-1252.
7. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
9. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
10. National Committee for Quality Assurance. The State of Health Care Quality: 2004. Washington, DC: National Committee for Quality Assurance, 2004. Available at www.ncqa.org/communications/SOMC/SOHC2004.pdf. Accessed March 18, 2005.
11. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care. 2004;27 (suppl 1):S65-S67.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703-717.
13. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
14. Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136:565-574.
15. George PB, Tobin KJ, Corpus RA, et al. Treatment of cardiac risk factors in diabetic patients: how well do we follow the guidelines? Am Heart J. 2001;142:857-863.